Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jul;39(7):1530–1537. doi: 10.1128/aac.39.7.1530

In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii.

M E Fichera 1, M K Bhopale 1, D S Roos 1
PMCID: PMC162776  PMID: 7492099

Abstract

In order to characterize the delayed effect of clindamycin and macrolide antibiotics against Toxoplasma gondii tachyzoites (E. R. Pfefferkorn and S. E. Borotz, Antimicrob. Agents Chemother. 38:31-37, 1994), we have carefully examined the replication of parasites as a function of time after drug addition. Intracellular tachyzoites treated with up to 20 microM clindamycin (> 1,000 times the 50% inhibitory concentration) exhibit doubling times indistinguishable from those of controls (approximately 7 h). Drug-treated parasites emerge from infected cells and establish parasitophorous vacuoles inside new host cells as efficiently as untreated controls, but replication within the second vacuole is dramatically slowed. Growth inhibition in the second vacuole does not require continued presence of drug, but it is dependent solely on the concentration and duration of drug treatment in the first (previous) vacuole. The susceptibility of intracellular parasites to nanomolar concentrations of clindamycin contrasts with that of extracellular tachyzoites, which are completely resistant to treatment, even through several cycles of subsequent intracellular replication. This peculiar phenotype, in which drug effects are observed only in the second infectious cycle, also characterizes azithromycin and chloramphenicol treatment, but not treatment with cycloheximide, tetracycline, or anisomycin. These findings provide new insights into the mode of clindamycin and macrolide action against T. gondii, although the relevant target for their action remains unknown.

Full Text

The Full Text of this article is available as a PDF (303.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beckers C. J., Roos D. S., Donald R. G., Luft B. J., Schwab J. C., Cao Y., Joiner K. A. Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics. J Clin Invest. 1995 Jan;95(1):367–376. doi: 10.1172/JCI117665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bermudes D., Peck K. R., Afifi M. A., Beckers C. J., Joiner K. A. Tandemly repeated genes encode nucleoside triphosphate hydrolase isoforms secreted into the parasitophorous vacuole of Toxoplasma gondii. J Biol Chem. 1994 Nov 18;269(46):29252–29260. [PubMed] [Google Scholar]
  3. Blais J., Tardif C., Chamberland S. Effect of clindamycin on intracellular replication, protein synthesis, and infectivity of Toxoplasma gondii. Antimicrob Agents Chemother. 1993 Dec;37(12):2571–2577. doi: 10.1128/aac.37.12.2571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chang H. R., Pechère J. C. In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. Antimicrob Agents Chemother. 1988 Apr;32(4):524–529. doi: 10.1128/aac.32.4.524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dannemann B., McCutchan J. A., Israelski D., Antoniskis D., Leport C., Luft B., Nussbaum J., Clumeck N., Morlat P., Chiu J. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med. 1992 Jan 1;116(1):33–43. doi: 10.7326/0003-4819-116-1-33. [DOI] [PubMed] [Google Scholar]
  6. Douthwaite S. Interaction of the antibiotics clindamycin and lincomycin with Escherichia coli 23S ribosomal RNA. Nucleic Acids Res. 1992 Sep 25;20(18):4717–4720. doi: 10.1093/nar/20.18.4717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gardner M. J., Feagin J. E., Moore D. J., Spencer D. F., Gray M. W., Williamson D. H., Wilson R. J. Organisation and expression of small subunit ribosomal RNA genes encoded by a 35-kilobase circular DNA in Plasmodium falciparum. Mol Biochem Parasitol. 1991 Sep;48(1):77–88. doi: 10.1016/0166-6851(91)90166-4. [DOI] [PubMed] [Google Scholar]
  8. Harris C., Salgo M. P., Tanowitz H. B., Wittner M. In vitro assessment of antimicrobial agents against Toxoplasma gondii. J Infect Dis. 1988 Jan;157(1):14–22. doi: 10.1093/infdis/157.1.14. [DOI] [PubMed] [Google Scholar]
  9. Harris E. H., Boynton J. E., Gillham N. W. Chloroplast ribosomes and protein synthesis. Microbiol Rev. 1994 Dec;58(4):700–754. doi: 10.1128/mr.58.4.700-754.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Harris E. H., Burkhart B. D., Gillham N. W., Boynton J. E. Antibiotic resistance mutations in the chloroplast 16S and 23S rRNA genes of Chlamydomonas reinhardtii: correlation of genetic and physical maps of the chloroplast genome. Genetics. 1989 Oct;123(2):281–292. doi: 10.1093/genetics/123.2.281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Haverkos H. W. Assessment of therapy for toxoplasma encephalitis. The TE Study Group. Am J Med. 1987 May;82(5):907–914. doi: 10.1016/0002-9343(87)90151-3. [DOI] [PubMed] [Google Scholar]
  12. Katlama C. Evaluation of the efficacy and safety of clindamycin plus pyrimethamine for induction and maintenance therapy of toxoplasmic encephalitis in AIDS. Eur J Clin Microbiol Infect Dis. 1991 Mar;10(3):189–191. doi: 10.1007/BF01964459. [DOI] [PubMed] [Google Scholar]
  13. Leport C., Raffi F., Matheron S., Katlama C., Regnier B., Saimot A. G., Marche C., Vedrenne C., Vilde J. L. Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy. Am J Med. 1988 Jan;84(1):94–100. doi: 10.1016/0002-9343(88)90014-9. [DOI] [PubMed] [Google Scholar]
  14. Luft B. J., Hafner R., Korzun A. H., Leport C., Antoniskis D., Bosler E. M., Bourland D. D., 3rd, Uttamchandani R., Fuhrer J., Jacobson J. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med. 1993 Sep 30;329(14):995–1000. doi: 10.1056/NEJM199309303291403. [DOI] [PubMed] [Google Scholar]
  15. Luft B. J., Remington J. S. Toxoplasmic encephalitis in AIDS. Clin Infect Dis. 1992 Aug;15(2):211–222. doi: 10.1093/clinids/15.2.211. [DOI] [PubMed] [Google Scholar]
  16. Mack D. G., McLeod R. New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrob Agents Chemother. 1984 Jul;26(1):26–30. doi: 10.1128/aac.26.1.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. McCabe R. E., Oster S. Current recommendations and future prospects in the treatment of toxoplasmosis. Drugs. 1989 Dec;38(6):973–987. doi: 10.2165/00003495-198938060-00008. [DOI] [PubMed] [Google Scholar]
  18. Pfefferkorn E. R., Borotz S. E. Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin. Antimicrob Agents Chemother. 1994 Jan;38(1):31–37. doi: 10.1128/aac.38.1.31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pfefferkorn E. R., Nothnagel R. F., Borotz S. E. Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant. Antimicrob Agents Chemother. 1992 May;36(5):1091–1096. doi: 10.1128/aac.36.5.1091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Roos D. S., Donald R. G., Morrissette N. S., Moulton A. L. Molecular tools for genetic dissection of the protozoan parasite Toxoplasma gondii. Methods Cell Biol. 1994;45:27–63. doi: 10.1016/s0091-679x(08)61845-2. [DOI] [PubMed] [Google Scholar]
  21. Schwab J. C., Beckers C. J., Joiner K. A. The parasitophorous vacuole membrane surrounding intracellular Toxoplasma gondii functions as a molecular sieve. Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):509–513. doi: 10.1073/pnas.91.2.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Schwab J. C., Cao Y., Slowik M. R., Joiner K. A. Localization of azithromycin in Toxoplasma gondii-infected cells. Antimicrob Agents Chemother. 1994 Jul;38(7):1620–1627. doi: 10.1128/aac.38.7.1620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sibley L. D. Interactions between Toxoplasma gondii and its mammalian host cells. Semin Cell Biol. 1993 Oct;4(5):335–344. doi: 10.1006/scel.1993.1040. [DOI] [PubMed] [Google Scholar]
  24. Sibley L. D., Niesman I. R., Asai T., Takeuchi T. Toxoplasma gondii: secretion of a potent nucleoside triphosphate hydrolase into the parasitophorous vacuole. Exp Parasitol. 1994 Nov;79(3):301–311. doi: 10.1006/expr.1994.1093. [DOI] [PubMed] [Google Scholar]
  25. Tenant-Flowers M., Boyle M. J., Carey D., Marriott D. J., Harkness J. L., Penny R., Cooper D. A. Sulphadiazine desensitization in patients with AIDS and cerebral toxoplasmosis. AIDS. 1991 Mar;5(3):311–315. doi: 10.1097/00002030-199103000-00011. [DOI] [PubMed] [Google Scholar]
  26. Wilson R. J., Gardner M. J., Feagin J. E., Williamson D. H. Have malaria parasites three genomes? Parasitol Today. 1991 Jun;7(6):134–136. doi: 10.1016/0169-4758(91)90276-t. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES